This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (168)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stephen A. Sherwin, MD; James A. Knost, MD; Seymour Fein, MD; Paul G. Abrams, MD; Kenneth A. Foon, MD; Jeffrey J. Ochs, MD; Carolyn Schoenberger, RN; Annette E. Maluish, PhD; Robert K. Oldham, MD

JAMA. 1982;248(19):2461-2466.

Abstract
Eighty-one patients with a variety of refractory disseminated malignant neoplasms have been treated in the first multiple fixed-dose phase I trial of recombinant leukocyte A interferon (IFL-rA). Each patient received IFL-rA by intramuscular injection, three times weekly for 28 days. Dosages were escalated in different patients from 1 to 136x10⁶ units per injection. The toxic reactions seen with IFL-rA resembled those of nonrecombinant leukocyte interferon and included fever, chills, fatigue, anorexia, myalgia, headache, occasional nausea and vomiting, and dose-dependent reversible leukopenia and hepatic transaminase elevations. The pharmacokinetics of IFL-rA were also comparable with nonrecombinant leukocyte interferon. Objective evidence of antitumor activity was seen in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease, breast cancer, and melanoma, indicating that IFL-rA, the first genetically engineered biological response modifier available for testing in cancer patients, is biologically active in vivo.

(JAMA 1982;248:2461-2466)

Author Affiliations
From the Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, Frederick Cancer Research Facility, Frederick, Md (Drs Sherwin, Knost, Abrams, Foon, Ochs, Maluish, and Oldham and Ms Schoenberger); and Hoffmann-La Roche Inc, Nutley, NJ (Dr Fein).

Footnotes
Reprint requests to the National Cancer Institute-Frederick Cancer Research Facility, Bldg 560, Frederick, MD 21701 (Dr Sherwin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interferon Alfa Induces Leukocyte Capillary Trapping in Rat Retinal Microcirculation
Nishiwaki et al.
Arch Ophthalmol 1996;114:726-730.
ABSTRACT  

Immune Interventions in Disease
FAHEY et al.
ANN INTERN MED 1987;106:257-274.
ABSTRACT  

Alpha-Interferon and Immune Hemolytic Anemia
AKARD et al.
ANN INTERN MED 1986;105:306-306.
ABSTRACT  

Effect of Intralesional {alpha}2-Interferon on Actinic Keratoses
Edwards et al.
Arch Dermatol 1986;122:779-782.
ABSTRACT  

Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy
CHAMPLIN et al.
ANN INTERN MED 1986;104:671-688.
ABSTRACT  

Recombinant Leukocyte A Interferon: An Active Agent in Advanced Cutaneous T-Cell Lymphomas
BUNN et al.
ANN INTERN MED 1984;101:484-487.
ABSTRACT  

Recombinant Leukocyte A Interferon in Advanced Breast Cancer: Results of a Phase II Efficacy Trial
SHERWIN et al.
ANN INTERN MED 1983;98:598-602.
ABSTRACT